| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 500mg |
| Targets |
Tafluprost ethyl amide targets the prostaglandin F (FP) receptor, a G protein-coupled receptor involved in the regulation of intraocular pressure. As a prostaglandin analogue, it binds to and activates the FP receptor in the eye. This activation leads to an increase in the outflow of aqueous humor through the uveoscleral pathway, thereby reducing intraocular pressure (IOP). The compound's effect on eyelash growth is also mediated through the FP receptor. Tafluprost ethyl amide is a derivative of tafluprost, which is a widely used drug for the treatment of glaucoma.
|
|---|---|
| ln Vitro |
In vitro, Tafluprost ethyl amide acts as a prostaglandin analogue with activity at the FP receptor. Its activity is characterized by its ability to bind to and activate the FP receptor, leading to downstream signaling that promotes aqueous humor outflow. The compound's effects on eyelash growth are also observed in vitro, where it can stimulate the proliferation of hair follicle cells. The compound is used in research to study the pharmacology of prostaglandin analogues and their effects on IOP and hair growth.
|
| ln Vivo |
In vivo, Tafluprost ethyl amide is a potent ocular hypotensive agent that reduces intraocular pressure (IOP). It is used in the treatment of glaucoma and ocular hypertension. The compound works by increasing the outflow of aqueous humor, thereby lowering IOP. It has also been shown to affect eyelash growth, making it useful for the treatment of eyelash hypotrichosis. Formulations containing tafluprost ethyl amide have been developed for use in anti-glaucoma eye drops and cosmetics.
|
| Enzyme Assay |
In vitro receptor binding assays for Tafluprost ethyl amide typically involve measuring its affinity for the prostaglandin F (FP) receptor. The compound is incubated with membrane preparations from cells expressing the FP receptor and a radiolabeled ligand specific for the receptor. The amount of bound radioligand is measured in the presence of varying concentrations of the compound to determine its binding affinity (Ki). Functional assays, such as measuring the activation of downstream signaling pathways (e.g., calcium mobilization), can also be used to assess the compound's agonist activity at the FP receptor.
|
| Cell Assay |
In vitro cell-based assays for Tafluprost ethyl amide are performed in cell lines expressing the FP receptor. Cells are treated with varying concentrations of the compound, and the activation of downstream signaling pathways is measured. For example, the compound's ability to stimulate calcium mobilization or cAMP production can be assessed. The compound's effects on cell proliferation and differentiation can also be studied in relevant cell types, such as hair follicle cells. The compound is typically dissolved in DMSO and diluted in cell culture medium for treatment.
|
| Animal Protocol |
In vivo animal experiments with Tafluprost ethyl amide would typically be conducted in animal models of glaucoma or ocular hypertension. The compound could be administered topically as eye drops to rabbits or monkeys, and the intraocular pressure (IOP) would be measured at various time points using a tonometer. The compound's ability to reduce IOP would be assessed by comparing the IOP in treated versus control eyes. The effects on eyelash growth could be evaluated in animal models by measuring eyelash length and thickness after topical application.
|
| ADME/Pharmacokinetics |
Tafluprost ethyl amide has a molecular weight of [not specified] and the formula C24H33F2NO4. It is a prostaglandin analogue and a derivative of the tafluprost free acid prodrug. The compound is intended for research use only. Its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, would be similar to those of other prostaglandin analogues. After topical ocular administration, it is absorbed through the cornea and reaches the target tissues in the eye.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for Tafluprost ethyl amide are not provided in the available sources. As a research chemical, its safety profile in humans has not been fully established. However, as a derivative of tafluprost, it is likely to have a similar safety profile. Tafluprost is generally well-tolerated, but it can cause side effects such as ocular hyperemia, irritation, and changes in eyelash growth. The compound is intended for research use only and is not for human consumption. Standard laboratory safety precautions should be followed when handling this compound.
|
| Additional Infomation |
Tafluprost ethyl amide is a prostaglandin analogue and a derivative of the tafluprost free acid prodrug. It has the molecular formula C24H33F2NO4. Tafluprost ethyl amide can reduce intraocular pressure (IOP) and affect eyelash growth. It is a potent ocular hypotensive agent that reduces IOP by increasing the outflow of aqueous humor. It is used in the treatment of glaucoma and ocular hypertension. Formulations containing tafluprost ethyl amide have also been used in the treatment of eyelash hypotrichosis and in cosmetics. The compound is intended for research use only.
|
| Molecular Formula |
C24H33F2NO4
|
|---|---|
| Molecular Weight |
437.5199
|
| Exact Mass |
437.237
|
| CAS # |
1185851-52-8
|
| Related CAS # |
1185851-52-8;
|
| PubChem CID |
71587943
|
| Appearance |
Colorless to light yellow viscous liquid
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
609.3±55.0 °C at 760 mmHg
|
| Flash Point |
322.3±31.5 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.559
|
| LogP |
2.66
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
31
|
| Complexity |
590
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
FC(C([H])([H])OC1C([H])=C([H])C([H])=C([H])C=1[H])(/C(/[H])=C(\[H])/[C@@]1([H])[C@@]([H])(C([H])([H])[C@@]([H])([C@]1([H])C([H])([H])/C(/[H])=C(/[H])\C([H])([H])C([H])([H])C([H])([H])C(N([H])C([H])([H])C([H])([H])[H])=O)O[H])O[H])F
|
| InChi Key |
VJZKLIPANASSBD-MSHHKXPZSA-N
|
| InChi Code |
InChI=1S/C24H33F2NO4/c1-2-27-23(30)13-9-4-3-8-12-19-20(22(29)16-21(19)28)14-15-24(25,26)17-31-18-10-6-5-7-11-18/h3,5-8,10-11,14-15,19-22,28-29H,2,4,9,12-13,16-17H2,1H3,(H,27,30)/b8-3-,15-14+/t19-,20-,21+,22-/m1/s1
|
| Chemical Name |
(Z)-7-[(1R,2R,3R,5S)-2-[(E)-3,3-difluoro-4-phenoxybut-1-enyl]-3,5-dihydroxycyclopentyl]-N-ethylhept-5-enamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2856 mL | 11.4280 mL | 22.8561 mL | |
| 5 mM | 0.4571 mL | 2.2856 mL | 4.5712 mL | |
| 10 mM | 0.2286 mL | 1.1428 mL | 2.2856 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
